Correlation Between MeiraGTx Holdings and Rocket Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both MeiraGTx Holdings and Rocket Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MeiraGTx Holdings and Rocket Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between MeiraGTx Holdings PLC and Rocket Pharmaceuticals, you can compare the effects of market volatilities on MeiraGTx Holdings and Rocket Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MeiraGTx Holdings with a short position of Rocket Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of MeiraGTx Holdings and Rocket Pharmaceuticals.

Diversification Opportunities for MeiraGTx Holdings and Rocket Pharmaceuticals

-0.57
  Correlation Coefficient

Excellent diversification

The 3 months correlation between MeiraGTx and Rocket is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding MeiraGTx Holdings PLC and Rocket Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rocket Pharmaceuticals and MeiraGTx Holdings is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MeiraGTx Holdings PLC are associated (or correlated) with Rocket Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rocket Pharmaceuticals has no effect on the direction of MeiraGTx Holdings i.e., MeiraGTx Holdings and Rocket Pharmaceuticals go up and down completely randomly.

Pair Corralation between MeiraGTx Holdings and Rocket Pharmaceuticals

Given the investment horizon of 90 days MeiraGTx Holdings PLC is expected to generate 0.96 times more return on investment than Rocket Pharmaceuticals. However, MeiraGTx Holdings PLC is 1.04 times less risky than Rocket Pharmaceuticals. It trades about 0.24 of its potential returns per unit of risk. Rocket Pharmaceuticals is currently generating about -0.08 per unit of risk. If you would invest  391.00  in MeiraGTx Holdings PLC on August 31, 2024 and sell it today you would earn a total of  264.00  from holding MeiraGTx Holdings PLC or generate 67.52% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

MeiraGTx Holdings PLC  vs.  Rocket Pharmaceuticals

 Performance 
       Timeline  
MeiraGTx Holdings PLC 

Risk-Adjusted Performance

18 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in MeiraGTx Holdings PLC are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, MeiraGTx Holdings showed solid returns over the last few months and may actually be approaching a breakup point.
Rocket Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Rocket Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward-looking signals remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

MeiraGTx Holdings and Rocket Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with MeiraGTx Holdings and Rocket Pharmaceuticals

The main advantage of trading using opposite MeiraGTx Holdings and Rocket Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MeiraGTx Holdings position performs unexpectedly, Rocket Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rocket Pharmaceuticals will offset losses from the drop in Rocket Pharmaceuticals' long position.
The idea behind MeiraGTx Holdings PLC and Rocket Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Fundamental Analysis
View fundamental data based on most recent published financial statements